NovaBay Pharmaceuticals, Inc. (NBY) Financials

NBY Assets vs Liabilities

DateAssetsLiabilities
Dec. 31, 2025 9.0 million 31.9 million
Sept. 30, 2025 3.5 million 1.9 million
June 30, 2025 6.9 million 2.7 million
March 31, 2025 9.9 million 3.7 million

NBY Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2025 -2.3 million 23000
Sept. 30, 2025 -1.8 million ?
June 30, 2025 -3.0 million 4000
March 31, 2025 -1.3 million 2000

NBY Net Income

No data available :(

NBY Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2025 8.0 million - 709000
Sept. 30, 2025 2.3 million - 821000
June 30, 2025 5.3 million - 931000
March 31, 2025 8.5 million - 1.0 million

NBY Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2025 5.8 million
Sept. 30, 2025 29.4 million
June 30, 2025 29.1 million
March 31, 2025 27.1 million

NBY Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2025 - - 1.8 million -
Sept. 30, 2025 - - 1.2 million -
June 30, 2025 - - 1.9 million -
March 31, 2025 - 10000 2.7 million 1.0 million

NBY Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2025 -521000 -479000
Sept. 30, 2025 521000 479000
June 30, 2025 - 38000
March 31, 2025 2.3 million 807000

NBY Revenue by Segment

Graph available only for paid members. Upgrade to see it.

NBY

Price: $1.88

52 week price:
1.11
99.75

Earnings Per Share: -28.50 USD

Exchange: ASE

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 100900

Market Capitalization: 51.9 million

Links: